deltatrials
Completed PHASE2 NCT00070174

Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy

Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study

Sponsor: Children's Oncology Group

Conditions Leukemia
Interventions allogeneic bone marrow transplantation asparaginase busulfan cyclophosphamide cyclosporine cytarabine daunorubicin hydrochloride etoposide gemtuzumab ozogamicin methotrexate mitoxantrone hydrochloride
Updated 7 times since 2017 Last updated: Feb 19, 2014 Started: Dec 31, 2003 Primary completion: Sep 30, 2006 Completion: Dec 31, 2013

A PHASE2 clinical study on Leukemia, this trial is completed. The trial is conducted by Children's Oncology Group and has accumulated 7 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Children's Oncology Group
  • National Cancer Institute (NCI)
Data source: Children's Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States, Albuquerque, United States, Amarillo, United States, Ann Arbor, United States, Asheville, United States, Atlanta, United States, Austin, United States, Baltimore, United States, Bangor, United States, Bern, Switzerland and 116 more location s